Tetraphase Pharmaceuticals, Inc. (TTPH) Reaches $3.58 After 4.00% Up Move; Blackrock Multi-sector Income Trust (BIT) Sentiment Is 1.94

June 29, 2018 - By Louis Casey

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Logo

The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) is a huge mover today! The stock increased 2.87% or $0.1 during the last trading session, reaching $3.58. About 234,760 shares traded. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has declined 48.55% since June 29, 2017 and is downtrending. It has underperformed by 61.12% the S&P500. Some Historical TTPH News: 15/05/2018 – 683 Capital Management Buys New 1.2% Position in Tetraphase; 21/04/2018 – DJ Tetraphase Pharmaceuticals Inc, Inst Holders, 1Q 2018 (TTPH); 06/03/2018 – Tetraphase Pharma 4Q Loss $23.5M; 14/05/2018 – Canada Pension Plan Invest Board Exits Position in Tetraphase; 15/05/2018 – Rock Springs Capital Management Exits Position in Tetraphase; 14/05/2018 – Fidelity Management & Research Exits Position in Tetraphase; 09/05/2018 – Tetraphase Presenting at UBS Conference May 21; 19/04/2018 – Tetraphase Pharmaceuticals to Present Data at the 38th Annual Meeting of the Surgical Infection Society; 30/04/2018 – $AKAO plazomicin BSI indication will be first drug under AdCom review for Limited Population Antibacterial Drug (LPAD) pathway, and will have important read-thru to other #antibiotics players; 19/03/2018 – TETRAPHASE PHARMACEUTICALS – BOARD ELECTED CHRISTOPHER WATT AS PRINCIPAL FINANCIAL OFFICER & PRINCIPAL ACCOUNTING OFFICER UNTIL CFO IS NAMEDThe move comes after 8 months positive chart setup for the $184.84 million company. It was reported on Jun, 29 by Barchart.com. We have $3.72 PT which if reached, will make NASDAQ:TTPH worth $7.39M more.

Blackrock Multi-sector Income Trust (BIT) investors sentiment increased to 1.94 in Q1 2018. It’s up 0.57, from 1.37 in 2017Q4. The ratio is more positive, as 31 funds increased or started new stock positions, while 16 decreased and sold their positions in Blackrock Multi-sector Income Trust. The funds in our database now own: 8.86 million shares, up from 8.36 million shares in 2017Q4. Also, the number of funds holding Blackrock Multi-sector Income Trust in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 12 Increased: 19 New Position: 12.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company has market cap of $184.84 million. The Company’s lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It currently has negative earnings. The firm has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy.

Analysts await Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) to report earnings on August, 1. They expect $-0.36 EPS, up 56.63% or $0.47 from last year’s $-0.83 per share. After $-0.42 actual EPS reported by Tetraphase Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -14.29% EPS growth.

More notable recent Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) news were published by: Globenewswire.com which released: “Detailed Research: Economic Perspectives on Tetraphase Pharmaceuticals, Tech Data, Southern National Bancorp of …” on June 21, 2018, also Seekingalpha.com with their article: “Tetraphase Pharma’s eravacycline shows positive effect in late-stage studies; shares up 6% premarket” published on June 11, 2018, Seekingalpha.com published: “Your Daily Pharma Scoop: Tetraphase Positive Data, MediWound In Phase 3, Allergan Moves Up” on June 13, 2018. More interesting news about Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) were released by: Streetinsider.com and their article: “Tetraphase Pharma (TTPH) Reports Positive Data from a Pooled Analysis of IGNITE1 and IGNITE4 Phase 3 Trials” published on June 11, 2018 as well as Globenewswire.com‘s news article titled: “Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)” with publication date: June 08, 2018.

Among 6 analysts covering Tetraphase Pharmaceutical (NASDAQ:TTPH), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Tetraphase Pharmaceutical had 12 analyst reports since February 12, 2018 according to SRatingsIntel. BMO Capital Markets maintained the shares of TTPH in report on Thursday, March 8 with “Market Perform” rating. Gabelli upgraded Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) on Thursday, March 29 to “Buy” rating. On Wednesday, February 21 the stock rating was maintained by FBR Capital with “Buy”. FBR Capital maintained it with “Buy” rating and $600 target in Monday, June 4 report. The rating was maintained by FBR Capital with “Buy” on Tuesday, February 27. The rating was initiated by FBR Capital with “Buy” on Monday, February 12. As per Wednesday, February 14, the company rating was maintained by SunTrust. As per Wednesday, February 14, the company rating was downgraded by BMO Capital Markets. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has “Buy” rating given on Wednesday, March 7 by FBR Capital. The rating was maintained by FBR Capital with “Buy” on Monday, June 11.

Investors sentiment decreased to 1.05 in 2018 Q1. Its down 0.14, from 1.19 in 2017Q4. It worsened, as 15 investors sold Tetraphase Pharmaceuticals, Inc. shares while 23 reduced holdings. 13 funds opened positions while 27 raised stakes. 19.93 million shares or 32.47% less from 29.51 million shares in 2017Q4 were reported. Teton Advsr Inc has 43,000 shares for 0.01% of their portfolio. Rhumbline Advisers holds 0% or 47,962 shares in its portfolio. State Board Of Administration Of Florida Retirement Sys owns 19,923 shares or 0% of their US portfolio. Jane Street Group Ltd Liability Corp holds 13,549 shares. 17,729 are owned by Weiss Asset Mngmt L P. Retail Bank Of Ny Mellon reported 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Fincl Bank Of Montreal Can, Ontario – Canada-based fund reported 1,618 shares. Alliancebernstein L P has 54,600 shares. State Street Corp stated it has 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Ny State Common Retirement Fund holds 0% or 44,300 shares. First Manhattan accumulated 140 shares or 0% of the stock. Morgan Stanley accumulated 122,843 shares or 0% of the stock. Deutsche National Bank Ag holds 440,857 shares or 0% of its portfolio. Axa invested in 0% or 216,337 shares. Quantbot Techs L P reported 428 shares.

Since January 9, 2018, it had 0 insider purchases, and 2 insider sales for $98,932 activity. $44,507 worth of stock was sold by Dumas Jacques on Tuesday, January 9.

Shaker Financial Services Llc holds 1.9% of its portfolio in BlackRock Multi-Sector Income Trust for 234,454 shares. Rivernorth Capital Management Llc owns 836,494 shares or 1.04% of their US portfolio. Moreover, E&G Advisors Lp has 0.69% invested in the company for 95,278 shares. The Georgia-based Vident Investment Advisory Llc has invested 0.32% in the stock. Jaffetilchin Investment Partners Llc, a Florida-based fund reported 57,411 shares.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.